232 related articles for article (PubMed ID: 25768997)
1. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):15-8. PubMed ID: 25768997
[No Abstract] [Full Text] [Related]
2. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
[No Abstract] [Full Text] [Related]
6. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
10. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
[TBL] [Abstract][Full Text] [Related]
11. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
12. Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.
Lu D; Gillespie WR; Girish S; Agarwal P; Li C; Hirata J; Chu YW; Kagedal M; Leon L; Maiya V; Jin JY
CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):401-408. PubMed ID: 28544534
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
[TBL] [Abstract][Full Text] [Related]
14. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
15. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D
Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353
[TBL] [Abstract][Full Text] [Related]
16. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Lasater EA; Amin DN; Bannerji R; Mali RS; Barrett K; Rys RN; Oeh J; Lin E; Sterne-Weiler T; Ingalla ER; Go M; Yu SF; Krem MM; Arthur C; Hahn U; Johnston A; Karur V; Khan N; Marlton P; Phillips T; Gritti G; Seymour JF; Tani M; Yuen S; Martin S; Chang MT; Rose CM; Pham VC; Polson AG; Chang Y; Wever C; Johnson NA; Jiang Y; Hirata J; Sampath D; Musick L; Flowers CR; Wertz IE
Am J Hematol; 2023 Mar; 98(3):449-463. PubMed ID: 36594167
[TBL] [Abstract][Full Text] [Related]
17. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Mehta A; Forero-Torres A
Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
[TBL] [Abstract][Full Text] [Related]
18. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
19. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
20. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
